Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial
Andrea Necchi / nature - Nature Medicine, Published online: 24 October 2026; doi:10.1038/s41591-026-04740-9As presented at the ESMO Congress 2026: In this exploratory, nonrandomized phase 2a trial, treatment of patients with immune checkpoint inhibitor-naive muscle-invasive bladd…
AI Summary: A phase 2a GDFATHER-NEO trial tested adding visugromab to neoadjuvant nivolumab for muscle‑invasive bladder cancer in patients who cannot receive cisplatin. Early results focus on safety, pathologic response and feasibility of bladder‑preserving strategies, highlighting whether the combo improves outcomes without adding prohibitive toxicity.
Related Stories
Atirmociclib reduces progression after prior CDK4/6 inhibition in endocrine‑resistant breast cancer / 7 hrs
Low pCR reported with trastuzumab‑deruxtecan in early breast cancer / 28 hrs
Merck and Moderna report positive phase‑3 melanoma vaccine results / 2 months
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 2 months
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 2 months
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 2 months
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Product Recall, Zoonotic Disease, Obesity, Price Transparency and look for the RSS link.
StackHealth Time Machine